Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →ML Fraud Detection Score: 89%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
23,945
Total Claims
$3.4M
Drug Cost
1,120
Beneficiaries
$3,048
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-8%
Opioid rate vs peers
2.1% vs 2.2% avg
+116%
Cost per patient vs peers
$3,048 vs $1,411 avg
+40%
Brand preference vs peers
14.9% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
ML fraud detection score of 89% indicates prescribing patterns with significant similarity to confirmed fraud cases. 18 out of 20 decision trees flagged this provider.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
2.1%
Opioid Rate
492
Opioid Claims
$5,956
Opioid Cost
8.5%
Long-Acting Rate
Brand vs Generic
Brand: 3,527 claims · $2.9M
Generic: 20,192 claims · $450K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 399 | $542K |
| Semaglutide | 229 | $298K |
| Dapagliflozin Propanediol | 200 | $257K |
| Apixaban | 230 | $209K |
| Empagliflozin | 160 | $208K |
| Rivaroxaban | 147 | $171K |
| Adalimumab | 11 | $171K |
| Insulin Glargine,hum.Rec.Anlog | 130 | $97K |
| Fluticasone/Umeclidin/Vilanter | 118 | $90K |
| Mirabegron | 85 | $60K |
| Linaclotide | 78 | $59K |
| Sitagliptin Phosphate | 40 | $55K |
| Lipase/Protease/Amylase | 18 | $42K |
| Evolocumab | 58 | $40K |
| Linagliptin | 38 | $38K |
Prescribing Profile
Patient Profile
73
Avg Age
43%
Female
1.44
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data